Introduction
One approach toward improving the outcome of treatment for patients with unresectable intrahepatic cancer involves the use of enzyme-prodrug gene therapy. We and others [1] [2] [3] [4] [5] [6] [7] [8] have focused on a gene therapy strategy using 5FC (5-fluorouracil) and CD (cytosine deaminase). CD deaminates the prodrug 5FC (5-fluorocytosine) into the cytotoxic and radiosensitizing agent 5FU. We have shown that, for the same extent of cytosine (to uracil) converting activity, yCD (yeast CD) is far more efficient at the conversion of 5FC to 5FU than bCD (bacterial CD) in both in vivo and in vitro models. 4, 5 We have also demonstrated in vivo (in flank tumors) that a cure rate of greater than 50% can be achieved using 5FC and radiation if approximately 10% of tumor cells were expressing yCD. 9 Although these experiments were encouraging, the ability to extrapolate these results to the treatment of intrahepatic cancer was limited by the use of the standard model system of athymic nude mice bearing subcutaneous tumors as xenografts. Substantial evidence suggests that although heterotopic (subcutaneous) models provide ease of tumor measurement, orthotopic models may better reflect tumor behavior. 10 Thus, an important step in the development of a clinical trial using the 5FC/yCD strategy would be to demonstrate regression in an intrahepatic cancer model. We chose to develop a model system in which tumor cells containing the luciferase gene emit light after parenteral administration of D-luciferin. An advantage of this approach is that individual liver tumors can be visualized serially and non-invasively in the same animal, which decreases both the number of animals needed to complete an experiment and the variability of results. We found that the 5FC produced tumor regression when approximately 10% of the cells expressed the transgene, and that the luciferin/luciferase system facilitates the evaluation of new therapeutics for visceral tumors. After obtaining these results with stable cell lines, we wished to determine if this system could be used to test gene therapy. For this purpose we constructed an adenoviral vector for yCD using an RSV promoter (AdRSVyCD). We assessed this vector first in a subcutaneous model and then in mice bearing intrahepatic tumors as xenografts.
Results
To find if there was a correlation between photon counts and the actual size of the tumor, HT-29luc cells were implanted in the left lobe of the liver of nude mice. Pilot experiments showed that tumors were typically detectable 7-10 days after implantation of 10 6 cells. Tumors as small as 8 mm 3 could be visualized (data not shown). The bioluminescence was measured every week for period of 1 month, then animals were killed and tumors were measured by calipers. After we found a correlation between tumor size and actual photon counts (photon counts = 225 ± 14 × size (mm) 3 and r 2 = 0.99) the therapy experiments were begun.
In the therapy experiment, animals bearing intrahepatic tumors composed of either 0, 10, or 100% yCD/HT-29luc cells ( Figure 1 ) were treated with 5FC (500 mg/kg given i.p. 5 days a week for 3 weeks). Therapy was started only after the tumor was visualized in each animal. Tumors containing 0% yCD/HT-29luc cells Gene Therapy showed continuous growth during treatment with 5FC until reaching a size approximately 10-12 times greater than pretreatment levels. 10% yCD/HT-29luc tumors demonstrated growth during the treatment period, but regressed after the 21 day treatment course was completed. None of these tumors doubled in volume compared with the pretreatment volume during the 40 day observation period after the completion of treatment. Three of these six tumors began to increase in size after initially undergoing a decrease. Three of six tumors composed of 100% yCD/HT-29luc cells doubled in size during treatment, but ultimately regressed and remained in continuous response during the observation period after treatment ( Figure 2 ). These results suggested that 5FC can be used to produce substantial tumor regression when approximately 10% of the cells express yCD.
We next determined if tumor response to 5FC therapy as measured by photon counts, or luminescence, correlated with the actual size of each tumor. Animals were imaged on the day of death, which was either when tumor size became excessive for animals with 0% yCD/HT-29luc cells, or on day 60 for the animals bearing tumors containing either 10% or 100% yCD/HT-29luc cells ( Figure 3 ). As a first approximation of tumor burden, we used tumor size measured with calipers. We found that there was a linear relationship between tumor size and photon counts (photon counts = 220 ± 34 × size (mm) 3 and r 2 = 0.85). We then assessed the tumors histologically. We found that the four tumors which deviated the most from the regression line were chiefly fibrotic and came from the either 10% or 100% yCD/HT-29luc treatment group (Figure 4 ). When these fibrotic tumors were excluded from the linear regression analysis, a stronger relationship between photon counts and tumor size (photon counts = 278 ± 32 × size (mm) 3 and r 2 = 0.97) was observed. These findings suggest that photon counts may be a better reflection of viable tumor burden than caliper measurements in tumors that produce a substantial amount of fibrosis.
After establishing this non-invasive, yCD-luciferase expressing liver-tumor model to study gene therapy we wanted to evaluate if yCD could be used in gene therapy for colorectal cancer in the liver. For this purpose we constructed an adenovirus carrying yCD under a RSV promoter. After finding that this virus could produce yCD enzyme in vitro, 11 we tested this virus in a subcutaneous HT-29 tumor model in nude mice by immunostaining for yCD. We found that about 10-15% of the cells were transduced with this virus ( Figure 5 ). We proceeded to pilot studies in which we administered this virus to subcutaneous tumors in therapy experiments. We found that, under the limited conditions that we explored, yCD adenovirus slowed tumor growth when combined with administration of 5FC ( Figure 6 ). Tumors treated under the same conditions were also assessed for yCD enzyme activity, expressed as the ability to convert 5FC to 5FU (see Materials and methods). We found that tumors injected with adenovirus containing yCD expressed 7.2 ± 1.3% 5FC to 5FU converting activity after the second injection with adenovirus. It was then important to determine if this virus could be used in gene therapy experiments in a more relevant model of colon cancer in the liver. We found that a single intraperitoneal administration of virus did lead to expression of yCD enzyme within intrahepatic tumors ( Figure 7 ). These data taken together with the finding that adenoviral administration combined with 5FC can slow growth in the subcutaneous model suggest that the intrahepatic model may be useful for testing approaches to gene therapy for intrahepatic cancer. 
Discussion
In this study, we have shown that 5FC can cause the regression of intrahepatic colon cancer when about 10% of the cells express yCD. As it has been shown that 10% (or more) of cells can be transduced by several different gene therapy approaches, 2,12 these results suggest that gene therapy with yCD has the potential to be an effective therapy in the treatment of colorectal cancer metastatic to the liver. These data also demonstrate that luciferin bioluminescence is a convenient and effective technique for assessing tumor burden for intrahepatic cancer. This technique permits each animal to begin treatment when the tumor reaches an appropriate size and to be used as its own control, thereby increasing the power of the study. Furthermore, the measurement of emitted photons after administration of D-luciferin may be a more accurate method of estimating tumor size than direct measurement with calipers, as the latter cannot differentiate viable tumor from fibrosis.
Attempts have been made to treat intrahepatic cancer using bCD gene therapy. In one study, rats were implanted with tumors made from cells containing bCD and treated with 5FC. 13 Animals were killed 15 days later, and tumor sizes were compared by the group. Some tumor regressions were demonstrated, which is consistent with the results of the current study. In addition, experiments using tail vein injection of replication-incompetent adenoviral vectors containing bCD have demonstrated slowing of intrahepatic tumor growth in a mouse model. 6 Although these studies suggest that the cytosine deaminase strategy has the potential to be effective in an intrahepatic model, it is important to note that dose-limiting toxicity in human beings for 5FC is intestinal toxicity resulting from conversion of 5FC to 5FU in the intestine by enteric bacteria. 14, 15 Thus it seems likely that a gene therapy strategy using bCD will generate similar levels of 5FU in the tumor and the intestine, which would be Gene Therapy anticipated to produce little or no therapeutic advantage compared with systemic 5FU. In contrast, the K m for the conversion of 5FC to 5FU for yCD is 22-fold lower than for bCD, 5 suggesting that the yCD strategy has a greater potential to generate cytotoxic and radiosensitizing levels of intratumoral 5FU with acceptable intestinal toxicity in a clinical application.
The recent development of GFP (green fluorescence protein) and luciferase-luciferin-based imaging has applicability to the measurement of tumor size. GFP is limited by light scattering, and it appears to be difficult to image tumors that are more than a 2-3 mm deep. 16 The luciferin-luciferase approach can be effectively applied to visceral tumors 17 and has been previously shown to correlate well with tumor volume in an orthotopic rat brain tumor model. 18 Our findings illustrate the potential for luciferin-luciferase imaging in two ways. First is that photon counts may provide a more accurate estimate of viable tumor size than caliper measurements in a tumor which shows residual fibrosis after treatment. We anticipate that techniques like MRI (magnetic resonance imaging) or CT (computed tomography), which can image both tumors and normal tissues, will ultimately complement the bioluminescence imaging approach.
A second finding demonstrating the potential of bioluminescent imaging concerns the ability to measure a tumor multiple times during treatment. This number of measurements would have required three to four times the number of animals using traditional 'sacrifice and measure' techniques. If we were only able to measure tumors at one time point (for instance, 60 days), we would have missed the initial growth phase of the 10% yCD tumors compared with 100% yCD tumors. As it has been shown that 5FU is produced within hours of 5FC administration in subcutaneous yCD/HT-29 tumors, 19 the initial growth phase of the tumors containing 10% yCD cells suggests that the effects of 5FU accumulate after daily administration of the prodrug 5FC until reaching a level that is inhibitory to the tumor.
A limitation of this study is that we chose a single dose (based on our previous data for tolerability 9 ) and schedule of 5FC. Although it is possible that a longer treatment course would have produced a better tumor response, we feel the dose and schedule that we used was sufficient to establish the feasibility of this approach. In addition, we used cells stably transduced with both the luciferase and yCD genes as proof of the principle that this form of gene therapy can successfully treat intrahepatic cancer. For actual gene therapy, we would need to construct a vector carrying both the luciferase and yCD genes to permit this approach to be used. Our pilot studies using yCD adenovirus suggest that such treatment is possible and can produce an anti-tumor response. Definitive experiments are underway.
Materials and methods

Vectors and cell lines
Recombinant retroviral plasmid encoding luciferase was constructed in the pLazarus (pLzrs) vector (kindly provided by Gary Nolan, Stanford University, Stanford, CA, USA). The luciferase gene was isolated from plasmid pGL3-basic vector (Promega, Madison, WI, USA) by PCR reaction (94°C for 1 min, 42°C for 30 s and 72°C for 3 min, 35 cycles). The 5' primer, GCG AAT TCG CCA CCA TGG AAG ACG CC, introduces both an EcoRI site and a Kozak ribosome binding sequence 5' to the coding sequence for luciferase. The 3' primer, GCG AAT TCC TAT TAC ACG GCG ATC TTT CCG CC, introduces an EcoRI site 3' to the coding sequence. To generate retrovirus, the pLzrs-luc or pLzrs-yCD was transfected into the amphoteric phiNX packaging cell line (kindly provided by Gary Nolan), using lipofectAMINE Plus (Life Technologies, Rockville, MD, USA) following the manufacturer's instructions. Supernatant from the transfected packaging cells was collected 48 h after transfection. The media was then centrifuged at 1000 g for 5 min, filtered through a 0.45-m filter, and stored at Ϫ80°C until use.
HT-29 human colon cancer cells were cultured in RPMI media containing 10% bovine serum in an atmosphere of 7% CO 2 as described previously. 20 Cells were checked for mycoplasma contamination on a routine basis. Cells were infected with retrovirus and selected in puromycin using standard techniques. The expression of luciferase was monitored as described below. We found that cells stably expressed the luciferase gene for at least 11 weeks after transplantation (data not shown). Yeast CD/HT-29luc cells were constructed by infecting HT-29luc cells with yCD retrovirus and selecting in G418. The resulting clones were assessed for both luciferase and yCD activity before they were injected in the liver of nude mice (Table  1) . We also found that the population doubling times of HT-29luc cells and of yCD/HT-29luc cells were similar (data not shown).
Mouse model of intrahepatic tumor
Mice were handled according to the established procedures of the University of Michigan Laboratory Animal Maintenance Manual. Eight-week-old nude female mice (Nu/Nu CD-1, Charles River Laboratories, Wilmington, MA, USA) were used. Mice were anesthetized with an intraperitoneal injection of xylazine (9 mg/kg) and ketamine (58 mg/kg). The left liver lobe was exteriorized through a 1 cm midline incision and held using sterile cotton-tipped swabs. Animals were divided into three groups for intrahepatic tumor cell inoculation with 10 6 viable cells, delivered through 30-gauge needle. Group I received 100% HT-29luc cells, group II received 100% yCD/HT-29luc cells, and group III was injected with a mixture of 10%, yCD/HT-29luc and 90% HT-29luc tumor cells. The peritoneal wall was sutured (Ethicon, Somerville, NJ, USA), and the body wall was closed by autoclips (MikRon Precision, Gardena, CA, USA). Animals were imaged after 10 days, and every 8-10 days once therapy was underway using an ICCD camera (see below). Tumor size was also measured in two dimensions at the time animals were killed, and the volume was calculated using the formula: /6 (length × width 2 ). Mice were treated 5 days a week (Monday-Friday) for 3 weeks with 5FC (500 mg/kg) i.p.
Imaging
Cells and tumors were imaged using an ICCD (intensified and ultra-cooled charged coupled device) camera (C2400-75H, Hamamatsu, Japan), fitted with a 50 mm f/0.95 Navitar TV lens (Navitar, Japan) which detects photons and assigns a value to each pixel corresponding to the number of photons at that location. Cultured cells were imaged by adding D-luciferin (0.15 mg/ml, Biosynth, Naperville, IL, USA) to the media and collecting photons for 1 min. We found that the presence of up to 10 M 5FU for up to 18 h did not affect the number of photons emitted (data not shown). To image tumors, animals were injected with 160 mg/kg D-luciferin i.p. They were anesthetized 15 min later by injecting with a mixture of xylazine (9 mg/kg) and ketamine (58 mg/kg) i.p. The animals were then placed in a light-tight specimen chamber, and a gray scale reference image was obtained. Photons emitted from the luciferase-luciferin reaction were collected and integrated for a period of 4 min. A pseudocolor image representing light intensity was generated on an Argus Image Processor (Hamamatsu, Japan). Images were transferred using a plug-in module and Image Intensifier M4314 (Hamamatsu) to a computer. Finally, gray scale reference images and pseudocolor images were superimposed.
Microscopy
Livers were fixed in Bouin's solution (Sigma, St Louis, MO, USA) overnight, washed in PBS and kept in 70% ethanol until use. Specimens were embedded in paraffin, and 8 m thick sections were cut and stained with hematoxylin and eosin for histological analysis using standard techniques.
Adenoviral plasmid construction
The yCD gene and the Kozak sequence from pZyCD 4 were amplified by PCR using primers (5' ATG AAG CTT TGT CCA CTC CCA GGT CC 3') and (5' CTA GAA GGC ACA GTC GAG GTT ACT ACT CAC CAA TAT CTT CAA ACC 3'). The bovine growth hormone poly-A tail from pSecTag-pA was amplified using primers 5' GGT TTG AAG ATA TTG GTG AGT AGT AAC CTC GAC TGT GCC TTC TAG 3' and 5' TAG CAG CTT TCC CCA GCATGC CTG CTA 3' and then fused to the yCD cDNA by overlap PCR. The entire 702-bp fragment carrying yCD polyA was sub cloned into pAdMCSloxp on a HindIII/HindIII site to yield pAd.yCDloxp. The integrity of the sequence was verified by sequencing.
Adenovirus production and titration Adenoviral constructs were generated by in vitro recombination. In brief, the yCD was inserted in an adenoviral shuttle plasmid (pAdMCSloxP) containing an RSV driven expression cassette. It was used to generate a replication defective adenoviral genome by cre/lox recombination with a cosmid, cs360loxP, containing most of the adenovirus type 5 backbone. Viruses were generated by transfection into the 293-complementation cell line. The resulting adenoviral constructs contain the dl309 E3 deletion, whereas the E1 region was replaced by the expression cassette containing, from 5' to 3', the RSV promoter. Virus was propagated in 911 cells and purified on a CsCl gradient. Purified viruses were stored in 10 mM Tris-HCl pH 7.4, 137 mM NaCl, 5 mM KCl, 1 mM MgCl 2 10% glycerol (by volume).
